Oral administration of angiotensin-(1-7) ameliorates type 2 diabetes in rats
Diabetes mellitus type 2 (DM2) is a disease with increasing importance in modern societies and insufficient treatment options. Pharmacological stimulation of insulin signaling, which is blunted in DM2, is a promising approach to treat this disease. It has been shown that activation of the angiotensi...
Guardado en:
Autor principal: | |
---|---|
Otros Autores: | , , , , , , , , , , |
Formato: | Capítulo de libro |
Lenguaje: | Inglés |
Publicado: |
Springer Verlag
2014
|
Materias: | |
Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
Aporte de: | Registro referencial: Solicitar el recurso aquí |
LEADER | 21428caa a22018617a 4500 | ||
---|---|---|---|
001 | PAPER-23957 | ||
003 | AR-BaUEN | ||
005 | 20230518205544.0 | ||
008 | 190411s2014 xx ||||fo|||| 00| 0 eng|d | ||
024 | 7 | |2 scopus |a 2-s2.0-84898472204 | |
024 | 7 | |2 cas |a 2 hydroxypropyl beta cyclodextrin, 94035-02-6; angiotensin[1-7], 39386-80-6; glucose, 50-99-7, 84778-64-3; glucose transporter 4, 188071-24-1; insulin, 9004-10-8; insulin receptor substrate 1, 175335-32-7; protein kinase B, 148640-14-6 | |
040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
030 | |a JMLME | ||
100 | 1 | |a Santos, S.H.S. | |
245 | 1 | 0 | |a Oral administration of angiotensin-(1-7) ameliorates type 2 diabetes in rats |
260 | |b Springer Verlag |c 2014 | ||
270 | 1 | 0 | |m Santos, R.A.S.; Department of Physiology and Biophysics, Biological Sciences Institute (ICB), Federal University of Minas Gerais (UFMG), Av Antonio Carlos 6627-ICB, 31270-901 Belo Horizonte MG, Brazil; email: robsonsant@gmail.com |
506 | |2 openaire |e Política editorial | ||
504 | |a Dandona, P., Aljada, A., A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis (2002) Am J Cardiol, 90, pp. 27G-33G. , 1:CAS:528:DC%2BD38XnvV2qsLw%3D 12231076 10.1016/S0002-9149(02)02556-0 | ||
504 | |a Mauvais-Jarvis, F., Kahn, C.R., Understanding the pathogenesis and treatment of insulin resistance and type 2 diabetes mellitus: What can we learn from transgenic and knockout mice? (2000) Diabetes Metab, 26, pp. 433-448. , 1:CAS:528:DC%2BD3MXhtl2iurk%3D 11173714 | ||
504 | |a Molitch, M.E., Defronzo, R.A., Franz, M.J., Keane, W.F., Mogensen, C.E., Parving, H.H., Steffes, M.W., Nephropathy in diabetes (2004) Diabetes Care, 27 (SUPPL. 1), pp. 79-S83. , 14693934 | ||
504 | |a Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease (2007) Am J Kidney Dis, 49, pp. 12-154. , KDOQI 10.1053/j.ajkd.2006.12.005 | ||
504 | |a Prasad, A., Quyyumi, A.A., Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome (2004) Circulation, 110, pp. 1507-1512. , 15364819 10.1161/01.CIR.0000141736.76561.78 | ||
504 | |a Giacchetti, G., Sechi, L.A., Rilli, S., Carey, R.M., The renin-angiotensin-aldosterone system, glucose metabolism and diabetes (2005) Trends Endocrinol Metab, 16, pp. 120-126. , 1:CAS:528:DC%2BD2MXivV2gs7o%3D 15808810 10.1016/j.tem.2005.02.003 | ||
504 | |a Strazzullo, P., Galletti, F., Impact of the renin-angiotensin system on lipid and carbohydrate metabolism (2004) Curr Opin Nephrol Hypertens, 13, pp. 325-332. , 15073492 10.1097/00041552-200405000-00010 | ||
504 | |a Gurley, S.B., Coffman, T.M., The renin-angiotensin system and diabetic nephropathy (2007) Semin Nephrol, 27, pp. 144-152. , 1:CAS:528:DC%2BD2sXlt1KrtL0%3D 17418683 10.1016/j.semnephrol.2007.01.009 | ||
504 | |a Putnam, K., Shoemaker, R., Yiannikouris, F., Cassis, L.A., The renin-angiotensin system: A target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome (2012) Am J Physiol Heart Circ Physiol, 302, pp. 1219-H1230. , 1:CAS:528:DC%2BC38XkslCis7c%3D 3311482 22227126 10.1152/ajpheart.00796. 2011 | ||
504 | |a Bader, M., Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy (2010) Ann Rev Pharmacol Toxicol, 50, pp. 439-465. , 1:CAS:528:DC%2BC3cXisVelu78%3D 10.1146/annurev.pharmtox.010909.105610 | ||
504 | |a Boustany, C.M., Bharadwaj, K., Daugherty, A., Brown, D.R., Randall, D.C., Cassis, L.A., Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension (2004) Am J Physiol Regul Integr Comp Physiol, 287, pp. 943-R949. , 1:CAS:528:DC%2BD2cXptF2mu78%3D 15191907 10.1152/ajpregu.00265.2004 | ||
504 | |a Crackower, M.A., Sarao, R., Oudit, G.Y., Yagil, C., Kozieradzki, I., Scanga, S.E., Oliveira-Dos-Santos, A.J., Pei, Y., Angiotensin-converting enzyme 2 is an essential regulator of heart function (2002) Nature, 417, pp. 822-828. , 1:CAS:528:DC%2BD38Xks1Wmurg%3D 12075344 10.1038/nature00786 | ||
504 | |a Santos, R.A., Ferreira, A.J., Pinheiro, S.V., Sampaio, W.O., Touyz, R., Campagnole-Santos, M.J., Angiotensin-(1-7) and its receptor as a potential targets for new cardiovascular drugs (2005) Expert Opin Investig Drugs, 14, pp. 1019-1031. , 1:CAS:528:DC%2BD2MXmvFelsr8%3D 16050794 10.1517/13543784.14.8.1019 | ||
504 | |a Tipnis, S.R., Hooper, N.M., Hyde, R., Karran, E., Christie, G., Turner, A.J., A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase (2000) J Biol Chem, 275, pp. 33238-33243. , 1:CAS:528:DC%2BD3cXnvVOqtbw%3D 10924499 10.1074/jbc.M002615200 | ||
504 | |a Reudelhuber, T.L., The renin-angiotensin system: Peptides and enzymes beyond angiotensin II (2005) Curr Opin Nephrol Hypertens, 14, pp. 155-159. , 1:CAS:528:DC%2BD2MXjtFWjsLs%3D 15687842 10.1097/00041552-200503000-00011 | ||
504 | |a Santos, R.A., Simoes Silva E, A.C., Maric, C., Silva, D.M.R., Machado, R.P., De Buhr, I., Heringer-Walther, S., Bader, M., Angiotensin-(1-7) is an endogenous ligand for the G-protein coupled receptor Mas (2003) Proc Natl Acad Sci U S A, 100, pp. 8258-8263. , 1:CAS:528:DC%2BD3sXlsFGnsbc%3D 166216 12829792 10.1073/pnas.1432869100 | ||
504 | |a Fraga Da Silva, R.A., Pinheiro, S.V.B., Goncalves, A.C.C., Alenina, N., Bader, M., Santos, R.A., The NO-mediated antithrombotic effect of angiotensin-(1-7) is abolished in mas-knockout mice (2008) Mol Med, 14, pp. 28-35 | ||
504 | |a Santos, R.A., Ferreira, A.J., Angiotensin-(1-7) and the renin-angiotensin system (2007) Curr Opin Nephrol Hypertens, 16, pp. 122-128. , 1:CAS:528:DC%2BD2sXjsFert7Y%3D 17293687 10.1097/MNH.0b013e328031f362 | ||
504 | |a Niu, M.J., Yang, J.K., Lin, S.S., Ji, X.J., Guo, L.M., Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice (2008) Endocrine, 34, pp. 56-61. , 1:CAS:528:DC%2BD1MXhvVWktbw%3D 18956256 10.1007/s12020-008-9110-x | ||
504 | |a Bindom, S.M., Hans, C.P., Xia, H., Boulares, A.H., Lazartigues, E., Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice (2010) Diabetes, 59, pp. 2540-2548. , 1:CAS:528:DC%2BC3cXhsVGhs7bP 3279528 20660625 10.2337/db09-0782 | ||
504 | |a Santos, S.H.S., Braga, J.F., Mario, E.G., Porto, L.C.J., Botion, L.M., Alenina, N., Bader, M., Santos, R.A., Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7) (2010) Arterioscler Thromb Vasc Biol, 30, pp. 953-961. , 1:CAS:528:DC%2BC3cXkslKqsrs%3D 20203301 10.1161/ATVBAHA.109.200493 | ||
504 | |a Giani, J.F., Mayer, M.A., Munoz, M.C., Silberman, E.A., Hocht, C., Taira, C.A., Gironacci, M.M., Dominici, F.P., Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats (2009) Am J Physiol Endocrinol Metab, 296, pp. 262-E271. , 1:CAS:528:DC%2BD1MXitVaqs7c%3D 19001546 10.1152/ajpendo.90678.2008 | ||
504 | |a Marcus, Y., Shefer, G., Sasson, K., Kohen, F., Limor, R., Pappo, O., Nevo, N., Berkutzki, T., Angiotensin 1-7 as means to prevent the metabolic syndrome: Lessons from the fructose-fed rat model (2013) Diabetes, 62, pp. 1121-1130. , 1:CAS:528:DC%2BC3sXpvFCktbc%3D 23250359 10.2337/db12-0792 | ||
504 | |a Benter, I.F., Yousif, M.H., Dhaunsi, G.S., Kaur, J., Chappell, M.C., Diz, D.I., Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats (2008) Am J Nephrol, 28, pp. 25-33. , 1:CAS:528:DC%2BD2sXhsVCnurzL 17890855 10.1159/000108758 | ||
504 | |a Dhaunsi, G.S., Yousif, M.H., Akhtar, S., Chappell, M.C., Diz, D.I., Benter, I.F., Angiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activities (2010) Eur J Pharmacol, 638, pp. 108-114. , 1:CAS:528:DC%2BC3cXntVSgu7g%3D 2907528 20447391 10.1016/j.ejphar.2010.04. 030 | ||
504 | |a Santos, S.H.S., Fernandes, L.R., Mario, E.G., Ferreira, A.V.M., Porto, L.C.J., Alvarez-Leite, J.I., Botion, L.M., Santos, R.A., Mas deficiency in FVB/N in mice produces marked changes in lipid and glycemic metabolism (2008) Diabetes, 57, pp. 340-347. , 1:CAS:528:DC%2BD1cXhvVOktrg%3D 18025412 10.2337/db07-0953 | ||
504 | |a Lula, I., Denadai, A.L., Resende, J.M., De Sousa, F.B., De Lima, G.F., Pilo-Veloso, D., Heine, T., Sinisterra, R.D., Study of angiotensin-(1-7) vasoactive peptide and its beta-cyclodextrin inclusion complexes: Complete sequence-specific NMR assignments and structural studies (2007) Peptides, 28, pp. 2199-2210. , 1:CAS:528:DC%2BD2sXht1aht7nJ 17904691 10.1016/j.peptides.2007.08.011 | ||
504 | |a Marques, F.D., Ferreira, A.J., Sinisterra, R.D., Jacoby, B.A., Sousa, F.B., Caliari, M.V., Silva, G.A., Souza, L.E., An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats (2011) Hypertension, 57, pp. 477-483. , 1:CAS:528:DC%2BC3MXitVOis70%3D 21282558 10.1161/HYPERTENSIONAHA.110. 167346 | ||
504 | |a Fraga-Silva, R.A., Costa-Fraga, F.P., Sousa, F.B., Alenina, N., Bader, M., Sinisterra, R.D., Santos, R.A., An orally-active formulation of angiotensin-(1-7) produces antithrombotic effect (2011) Clinics, 66, pp. 837-841. , 3109384 21789389 10.1590/S1807-59322011000500021 | ||
504 | |a Kotnik, K., Popova, E., Todiras, M., Mori, M.A., Alenina, N., Seibler, J., Bader, M., Inducible transgenic rat model for diabetes mellitus based on shRNA-mediated gene knockdown (2009) PLoS ONE, 4, p. 5124. , 2659743 19340286 10.1371/journal.pone.0005124 | ||
504 | |a Nigro, J., Osman, N., Dart, A.M., Little, P.J., Insulin resistance and atherosclerosis (2006) Endocr Rev, 27, pp. 242-259. , 1:CAS:528:DC%2BD28XlsFamsL0%3D 16492903 10.1210/er.2005-0007 | ||
504 | |a Defronzo, R.A., Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis (1997) Neth J Med, 50, pp. 191-197. , 1:CAS:528:DyaK2sXitVKqtLc%3D 9175399 10.1016/S0300-2977(97)00012-0 | ||
504 | |a Grundy, S.M., Pre-diabetes, metabolic syndrome, and cardiovascular risk (2012) J Am Coll Cardiol, 59, pp. 635-643. , 1:CAS:528:DC%2BC38Xit1aqurw%3D 22322078 10.1016/j.jacc.2011.08.080 | ||
504 | |a Miranda, P.J., Defronzo, R.A., Califf, R.M., Guyton, J.R., Metabolic syndrome: Definition, pathophysiology, and mechanisms (2005) Am Heart J, 149, pp. 33-45. , 1:CAS:528:DC%2BD2MXht1yktrk%3D 15660032 10.1016/j.ahj.2004.07.013 | ||
504 | |a Hainault, I., Nebout, G., Turban, S., Ardouin, B., Ferre, P., Quignard-Boulange, A., Adipose tissue-specific increase in angiotensinogen expression and secretion in the obese (fa/fa) Zucker rat (2002) Am J Physiol Endocrinol Metab, 282, pp. 59-E66. , 1:CAS:528:DC%2BD38XlsVKltw%3D%3D 11739084 | ||
504 | |a Batlle, D., Wysocki, J., Soler, M.J., Ranganath, K., Angiotensin-converting enzyme 2: Enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy (2012) Kidney Int, 81, pp. 520-528. , 1:CAS:528:DC%2BC38Xjt1arsLc%3D 22113528 10.1038/ki.2011.381 | ||
504 | |a Singh, T., Singh, K., Sharma, P.L., Ameliorative potential of angiotensin1-7/Mas receptor axis in streptozotocin-induced diabetic nephropathy in rats (2010) Methods Find Exp Clin Pharmacol, 32, pp. 19-25. , 1:CAS:528:DC%2BC3cXntValsLs%3D 20383342 10.1358/mf.2010.32.1.1434160 1434160 | ||
504 | |a Giani, J.F., Munoz, M.C., Pons, R.A., Cao, G., Toblli, J.E., Turyn, D., Dominici, F.P., Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats (2011) Am J Physiol Ren Physiol, 300, pp. 272-F282. , 1:CAS:528:DC%2BC3MXhslWntLk%3D 10.1152/ajprenal.00278.2010 | ||
504 | |a Giani, J.F., Burghi, V., Veiras, L.C., Tomat, A., Munoz, M.C., Cao, G., Turyn, D., Dominici, F.P., Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats (2012) Am J Physiol Ren Physiol, 302, pp. 1606-F1615. , 1:CAS:528:DC%2BC38XhtVGntrzN 10.1152/ajprenal.00063.2012 | ||
504 | |a Pinheiro, S.V.B., Ferreira, A.J., Kitten, G.T., Da Silveira, K.D., Da Silva, D.A., Santos, S.H.S., Gava, E., Da Mota, R.K., Genetic deletion of the angiotensin(1-7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria (2009) Kidney Int, 75, pp. 1184-1193. , 1:CAS:528:DC%2BD1MXlvV2htL0%3D 19262461 10.1038/ki.2009.61 | ||
504 | |a Taniguchi, C.M., Emanuelli, B., Kahn, C.R., Critical nodes in signalling pathways: Insights into insulin action (2006) Nat Rev Mol Cell Biol, 7, pp. 85-96. , 1:CAS:528:DC%2BD28XhtlWnsLw%3D 16493415 10.1038/nrm1837 | ||
504 | |a Folli, F., Kahn, C.R., Hansen, H., Bouchie, J.L., Feener, E.P., Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk (1997) J Clin Invest, 100, pp. 2158-2169. , 1:CAS:528:DyaK2sXnt1Ggs78%3D 508410 9410892 10.1172/JCI119752 | ||
504 | |a Folli, F., Saad, M.J., Velloso, L., Hansen, H., Carandente, O., Feener, E.P., Kahn, C.R., Crosstalk between insulin and angiotensin II signalling systems (1999) Exp Clin Endocrinol Diabetes, 107, pp. 133-139. , 1:CAS:528:DyaK1MXitlyqs7c%3D 10320054 10.1055/s-0029-1212088 | ||
504 | |a Giani, J.F., Gironacci, M.M., Munoz, M.C., Pena, C., Turyn, D., Dominici, F.P., Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: Role of the AT1 and Mas receptors (2007) Am J Physiol Heart Circ Physiol, 293, pp. 1154-H1163. , 1:CAS:528:DC%2BD2sXptlyrsrc%3D 17496209 10.1152/ajpheart.01395.2006 | ||
504 | |a Sampaio, W.O., Souza Dos Santos, R.A., Faria-Silva, R., Mata Machado, L.T., Schiffrin, E.L., Touyz, R.M., Angiotensin-(1-7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways (2007) Hypertension, 49, pp. 185-192. , 1:CAS:528:DC%2BD28XhtlSrs7jF 17116756 10.1161/01.HYP.0000251865.35728.2f | ||
504 | |a Munoz, M.C., Giani, J.F., Burghi, V., Mayer, M.A., Carranza, A., Taira, C.A., Dominici, F.P., The Mas receptor mediates modulation of insulin signaling by angiotensin-(1-7) (2012) Regul Pept, 177, pp. 1-11. , 1:CAS:528:DC%2BC38Xns1Cjt7s%3D 22561450 10.1016/j.regpep.2012.04.001 | ||
504 | |a Hotamisligil, G.S., Peraldi, P., Budavari, A., Ellis, R., White, M.F., Spiegelman, B.M., IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance (1996) Science, 271, pp. 665-668. , 1:CAS:528:DyaK28XptVyhtQ%3D%3D 8571133 10.1126/science.271.5249.665 | ||
504 | |a Aguirre, V., Werner, E.D., Giraud, J., Lee, Y.H., Shoelson, S.E., White, M.F., Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action (2002) J Biol Chem, 277, pp. 1531-1537. , 1:CAS:528:DC%2BD38XnvFyjtQ%3D%3D 11606564 10.1074/jbc.M101521200 | ||
504 | |a Andreozzi, F., Laratta, E., Sciacqua, A., Perticone, F., Sesti, G., Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells (2004) Circ Res, 94, pp. 1211-1218. , 1:CAS:528:DC%2BD2cXjs1yltbk%3D 15044323 10.1161/01.RES.0000126501.34994. 96 | ||
504 | |a Liu, C., Lv, X.H., Li, H.X., Cao, X., Zhang, F., Wang, L., Yu, M., Yang, J.K., Angiotensin-(1-7) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes (2012) Acta Diabetol, 49, pp. 291-299. , 1:CAS:528:DC%2BC38XhtFaks7nP 22042130 10.1007/s00592-011-0348-z | ||
504 | |a Mario, E.G., Santos, S.H., Ferreira, A.V., Bader, M., Santos, R.A., Botion, L.M., Angiotensin-(1-7) Mas-receptor deficiency decreases peroxisome proliferator-activated receptor gamma expression in adipocytes (2012) Peptides, 33, pp. 174-177. , 1:CAS:528:DC%2BC38XovF2msg%3D%3D 22119778 10.1016/j.peptides.2011.11.014 | ||
520 | 3 | |a Diabetes mellitus type 2 (DM2) is a disease with increasing importance in modern societies and insufficient treatment options. Pharmacological stimulation of insulin signaling, which is blunted in DM2, is a promising approach to treat this disease. It has been shown that activation of the angiotensin (Ang)-(1-7)/Mas axis of the renin-angiotensin system leads to an improved glucose uptake. In this study, we intended to evaluate, whether this effect could be exploited therapeutically. We first confirmed that Ang-(1-7) improves insulin signaling and glucose uptake in vitro in cultured cardiomyocytes. We then evaluated the therapeutic effect of a newly developed hydro-xypropyl- β-cyclodextrin-based Ang-(1-7) nano-formulation in a novel transgenic rat model of inducible insulin resistance and DM2. The chronic administration of this compound prevented the marked elevation in blood glucose levels in these rats at a dose of 30 μg/kg, reversed the established hyperglycemic state at a dose of 100 μg/kg, and resulted in improved insulin sensitivity, reduced plasma insulin and decreased diabetic nephropathy. In conclusion, an oral Ang-(1-7) formulation reverses hyperglycemia and its consequences in an animal model of DM2 and represents a novel therapeutic option for the treatment of DM2 and other cardio-metabolic diseases. Key message: A novel rat model with inducible diabetes can be used to evaluate new therapies. Angiotensin-(1-7) is effective in an oral formulation packaged in cyclodextrine. Angiotensin-(1-7) is a promising antidiabetic drug. © 2013 Springer-Verlag Berlin Heidelberg. |l eng | |
593 | |a Department of Physiology and Biophysics, Biological Sciences Institute (ICB), Federal University of Minas Gerais (UFMG), Av Antonio Carlos 6627-ICB, 31270-901 Belo Horizonte MG, Brazil | ||
593 | |a Instituto de Química y Fisicoquímica Biológicas, Departamento de Química Biológica, Universidad de Buenos Aires, Junín 956, (1113) Buenos Aires, Argentina | ||
593 | |a Max-Delbrück-Center for Molecular Medicine (MDC), Buch, 13125 Berlin, Germany | ||
690 | 1 | 0 | |a ANGIOTENSIN-(1-7) |
690 | 1 | 0 | |a ANTIDIABETIC |
690 | 1 | 0 | |a RNA INTERFERENCE |
690 | 1 | 0 | |a 2 HYDROXYPROPYL BETA CYCLODEXTRIN |
690 | 1 | 0 | |a ANGIOTENSIN[1-7] |
690 | 1 | 0 | |a GLUCOSE |
690 | 1 | 0 | |a GLUCOSE TRANSPORTER 4 |
690 | 1 | 0 | |a GLYCOGEN SYNTHASE KINASE 3BETA |
690 | 1 | 0 | |a INSULIN |
690 | 1 | 0 | |a INSULIN RECEPTOR |
690 | 1 | 0 | |a INSULIN RECEPTOR SUBSTRATE 1 |
690 | 1 | 0 | |a PROTEIN KINASE B |
690 | 1 | 0 | |a ANIMAL CELL |
690 | 1 | 0 | |a ANIMAL CELL CULTURE |
690 | 1 | 0 | |a ANIMAL EXPERIMENT |
690 | 1 | 0 | |a ANIMAL MODEL |
690 | 1 | 0 | |a ANIMAL TISSUE |
690 | 1 | 0 | |a ANTIDIABETIC ACTIVITY |
690 | 1 | 0 | |a ARTICLE |
690 | 1 | 0 | |a BODY WEIGHT |
690 | 1 | 0 | |a CELL ISOLATION |
690 | 1 | 0 | |a CELL MEMBRANE |
690 | 1 | 0 | |a CONTROLLED STUDY |
690 | 1 | 0 | |a DIABETIC NEPHROPATHY |
690 | 1 | 0 | |a DIURESIS |
690 | 1 | 0 | |a DOWN REGULATION |
690 | 1 | 0 | |a DRUG FORMULATION |
690 | 1 | 0 | |a ENZYME PHOSPHORYLATION |
690 | 1 | 0 | |a GLUCOSE BLOOD LEVEL |
690 | 1 | 0 | |a GLUCOSE TRANSPORT |
690 | 1 | 0 | |a HEART MUSCLE CELL |
690 | 1 | 0 | |a HISTOLOGY |
690 | 1 | 0 | |a HYPERGLYCEMIA |
690 | 1 | 0 | |a IMMUNOBLOTTING |
690 | 1 | 0 | |a IN VITRO STUDY |
690 | 1 | 0 | |a INSULIN BLOOD LEVEL |
690 | 1 | 0 | |a INSULIN RESISTANCE |
690 | 1 | 0 | |a INSULIN SENSITIVITY |
690 | 1 | 0 | |a LONG TERM CARE |
690 | 1 | 0 | |a MALE |
690 | 1 | 0 | |a NEWBORN |
690 | 1 | 0 | |a NON INSULIN DEPENDENT DIABETES MELLITUS |
690 | 1 | 0 | |a NONHUMAN |
690 | 1 | 0 | |a PREVENTION STUDY |
690 | 1 | 0 | |a RAT |
690 | 1 | 0 | |a SIGNAL TRANSDUCTION |
690 | 1 | 0 | |a THERAPY EFFECT |
690 | 1 | 0 | |a URINE VOLUME |
690 | 1 | 0 | |a ADMINISTRATION, ORAL |
690 | 1 | 0 | |a ANGIOTENSIN I |
690 | 1 | 0 | |a ANIMALS |
690 | 1 | 0 | |a ANIMALS, NEWBORN |
690 | 1 | 0 | |a DEOXYGLUCOSE |
690 | 1 | 0 | |a DIABETES MELLITUS, TYPE 2 |
690 | 1 | 0 | |a HYPERGLYCEMIA |
690 | 1 | 0 | |a HYPOGLYCEMIC AGENTS |
690 | 1 | 0 | |a INSULIN |
690 | 1 | 0 | |a MALE |
690 | 1 | 0 | |a MYOCYTES, CARDIAC |
690 | 1 | 0 | |a PEPTIDE FRAGMENTS |
690 | 1 | 0 | |a PHOSPHORYLATION |
690 | 1 | 0 | |a PROTO-ONCOGENE PROTEINS C-AKT |
690 | 1 | 0 | |a RATS |
690 | 1 | 0 | |a RATS, SPRAGUE-DAWLEY |
690 | 1 | 0 | |a SIGNAL TRANSDUCTION |
650 | 1 | 7 | |2 spines |a DIABETES |
700 | 1 | |a Giani, J.F. | |
700 | 1 | |a Burghi, V. | |
700 | 1 | |a Miquet, J.G. | |
700 | 1 | |a Qadri, F. | |
700 | 1 | |a Braga, J.F. | |
700 | 1 | |a Todiras, M. | |
700 | 1 | |a Kotnik, K. | |
700 | 1 | |a Alenina, N. | |
700 | 1 | |a Dominici, F.P. | |
700 | 1 | |a Santos, R.A.S. | |
700 | 1 | |a Bader, M. | |
773 | 0 | |d Springer Verlag, 2014 |g v. 92 |h pp. 255-265 |k n. 3 |p J. Mol. Med. |x 09462716 |t Journal of Molecular Medicine | |
856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-84898472204&doi=10.1007%2fs00109-013-1087-0&partnerID=40&md5=1f97e102b2e0be940608d8dd68a71c17 |y Registro en Scopus |
856 | 4 | 0 | |u https://doi.org/10.1007/s00109-013-1087-0 |y DOI |
856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_09462716_v92_n3_p255_Santos |y Handle |
856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_09462716_v92_n3_p255_Santos |y Registro en la Biblioteca Digital |
961 | |a paper_09462716_v92_n3_p255_Santos |b paper |c PE | ||
962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
999 | |c 84910 |